New nomenclature and DNA testing guidelines for myotonic dystrophy type 1 (DM1). The International Myotonic Dystrophy Consortium (IDMC)

Autor: Ashizawa, T, Gonzales, I, Ohsawa, N, Singer, RH, Devillers, M, Balasubramanyam, A, Cooper, TA, Khajavi, M, Lia-Baldini, A-S, Miller, G, Philips, AV, Timchenko, LT, Waring, J, Yamagata, H, Barbet, JP, Klesert, TR, Tapscott, SJ, Roses, AD, Wagner, M, Baiget, M, Martorell, L, Browne, GB, Eymard, B, Gourdon, G, Junien, C, Seznec, H, Carey, N, Gosling, M, Maire, P, Gennarelli, M, Sato, S, Ansved, T, Kvist, U, Eriksson, M, Furling, D, Chen, EJ, Housman, DE, Luciano, B, Siciliano, M, Spring, N, Shimizu, M, Eddy, E, Morris, GE, Krahe, R, Furuya, H, Adelman, J, Pribnow, D, Furutama, D, Mathieu, J, Hilton-Jones, D, Kinoshita, M, Abbruzzese, C, Sinden, RR, Wells, RD, Pearson, CE, Kobayashi, T, Johansson, A, Salvatori, S, Perryman, B, Swanson, M, Gould, FK, Harris, SE, Johnson, K, Mitchell, AM, Monckton, DG, Winchester, CL, Antonini, G, Day, JW, Liquori, C, Ranum, LPW, Westerlaken, J, Wieringa, B, Griffith, JD, Michalowski, S, Moore, H, Hamshere, M, Korade, Z, Thornton, CA, Jaeger, H, Lehmann, F, Moorman, JR, Mounsey, JP, Mahadevan, MS

Publikováno v: Neurology. 54(6)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::75d2ccaf6324132c2461cd0e15991c08
http://ora.ox.ac.uk/objects/uuid:66f50c67-8ab4-4599-a3c3-d41f33d01c65

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Altered functional brain network connectivity and glutamate system function in transgenic mice expressing truncated Disrupted-in-Schizophrenia 1.

Autor: Dawson N; 1] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK [2] Centre for Neuroscience (CeNsUS), University of Strathclyde, Glasgow, UK [3] Psychiatric Research Institute for Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK., Kurihara M; School of Physiology and Pharmacology, University of Bristol, Bristol, UK., Thomson DM; 1] Psychiatric Research Institute for Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK [2] Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK., Winchester CL; 1] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK [2] Centre for Neuroscience (CeNsUS), University of Strathclyde, Glasgow, UK [3] Psychiatric Research Institute for Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK., McVie A; 1] Centre for Neuroscience (CeNsUS), University of Strathclyde, Glasgow, UK [2] Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK., Hedde JR; Pfizer Neuroscience Research Unit, Cambridge, MA, USA., Randall AD; 1] School of Physiology and Pharmacology, University of Bristol, Bristol, UK [2] University of Exeter Medical School, University of Exeter, Hatherly Laboratories, Exeter, UK., Shen S; 1] School of Medical Sciences, Institute of Medical Sciences, University of Aberdeen, Aberdeen, UK [2] Regenerative Medicine Institute, School of Medicine, National University of Ireland, Galway, Ireland., Seymour PA; Pfizer Neuroscience Research Unit, Cambridge, MA, USA., Hughes ZA; Pfizer Neuroscience Research Unit, Cambridge, MA, USA., Dunlop J; Pfizer Neuroscience Research Unit, Cambridge, MA, USA., Brown JT; 1] School of Physiology and Pharmacology, University of Bristol, Bristol, UK [2] University of Exeter Medical School, University of Exeter, Hatherly Laboratories, Exeter, UK., Brandon NJ; Pfizer Neuroscience Research Unit, Cambridge, MA, USA., Morris BJ; 1] Psychiatric Research Institute for Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK [2] Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK., Pratt JA; 1] Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde, Glasgow, UK [2] Centre for Neuroscience (CeNsUS), University of Strathclyde, Glasgow, UK [3] Psychiatric Research Institute for Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow, UK.

Publikováno v: Translational psychiatry [Transl Psychiatry] 2015 May 19; Vol. 5, pp. e569. Date of Electronic Publication: 2015 May 19.

Risk genes for schizophrenia: translational opportunities for drug discovery.

Autor: Winchester CL; Psychiatric Research Institute of Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow G12 8QQ, UK; CeNsUS, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK; Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK., Pratt JA; Psychiatric Research Institute of Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow G12 8QQ, UK; CeNsUS, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow G4 0RE, UK. Electronic address: J.a.pratt@strath.ac.uk., Morris BJ; Psychiatric Research Institute of Neuroscience in Glasgow (PsyRING), Universities of Glasgow and Strathclyde, Glasgow G12 8QQ, UK; Institute of Neuroscience and Psychology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8QQ, UK.

Publikováno v: Pharmacology & therapeutics [Pharmacol Ther] 2014 Jul; Vol. 143 (1), pp. 34-50. Date of Electronic Publication: 2014 Feb 19.